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Abstract
Genetic risk prediction of chronic conditions including obesity, diabetes and CVD currently has limited predictive power but its potential to
engage healthy behaviour change has been of immense research interest. We aimed to understand whether the latter is indeed true by
conducting a systematic review and meta-analysis investigating whether genetic risk communication affects motivation and actual behaviour
change towards preventative lifestyle modiﬁcation. We included all randomised controlled trials (RCT) since 2003 investigating the impact of
genetic risk communication on health behaviour to prevent cardiometabolic disease, without restrictions on age, duration of intervention or
language. We conducted random-effects meta-analyses for perceived motivation for behaviour change and clinical changes (weight loss) and
a narrative analysis for other outcomes. Within the thirteen studies reviewed, ﬁve were vignette studies (hypothetical RCT) and seven were
clinical RCT. There was no consistent effect of genetic risk on actual motivation for weight loss, perceived motivation for dietary change
(control v. genetic risk group standardised mean difference (SMD) −0·15; 95% CI −1·03, 0·73, P= 0·74) or actual change in dietary behaviour.
Similar results were observed for actual weight loss (control v. high genetic risk SMD 0·29 kg; 95% CI −0·74, 1·31, P= 0·58). This review found
no clear or consistent evidence that genetic risk communication alone either raises motivation or translates into actual change in dietary intake
or physical activity to reduce the risk of cardiometabolic disorders in adults. Of thirteen studies, eight were at high or unclear risk of bias.
Additional larger-scale, high-quality clinical RCT are warranted.
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Personalised nutrition has been described as nutritional advice
formulated according to an individual’s characteristics or that
of a population subgroup(1). Such personal characteristics
may include phenotypic features and dietary preferences,
with age and sex as features of personalisation evident in
current nutritional guidelines(1). Recently, genetics has been
proposed to help further reﬁne personalised nutrition. High
expectations have been expressed regarding the potential for
translating research about lifestyle–gene interactions into per-
sonalised nutrition and also that learning about personalised
genetic risk may increase the adoption of healthy lifestyle
behaviours(2–5). Certainly, genetic risk may be a potent
motivator for behaviour change because of its biological
accuracy and personal salience, which is consistent with the
Health Belief Model(6). On the basis of this, a burgeoning
number of companies are providing direct-to-consumer (DTC)
genetic testing, which appear to be gaining popularity with the
public, despite the clinical validity and utility being as yet
unclear(7,8).
Earlier studies have indicated that the provision of persona-
lised genetic information favourably inﬂuences screening
behaviours and medication adherence for individuals at risk of
familial cancers, often involving Mendelian inheritance with
high-penetrance genetic variants(9). However, this cannot be
assumed for the adoption of more complex ‘lifestyle’ health-
related behaviours, such as dietary modiﬁcation, which are
required to be adopted and sustained in order to reduce the risk
of developing cardiometabolic disorders such as obesity, type 2
diabetes (T2D) and CVD. These highly prevalent conditions
have low-penetrance susceptibility genetic variants plus a
multifactorial aetiology. A cochrane systematic review in 2010
found little or no effect of the provision of genetic disease risk
estimates on change in physical activity or dietary behaviours,
although from a limited number of available studies with poor
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quality(10). This and other reviews make similar conclusions,
including the largest DTC-based cohort study to date
(n 2037)(11–14). Although these were largely based on vignette
studies (where participants were provided with an imaginary
scenario of their genetic risk), recently the evidence has been
enhanced by a number of clinical intervention studies.
At present, many DTC companies are providing genetic testing
for multifactorial conditions predicated on the above hypothesis
in order to meet public demand(15), but dangerously they are
embedded in an environment without regulatory frameworks to
protect against misuse of DTC services(16). Therefore, a sys-
tematic evaluation that captures these newer studies is warranted
to help clarify the motivational impact of genetic risk information
and its effect on actual behaviour and clinical outcome.
Therefore, we performed a systematic review and meta-
analysis of randomised controlled trials (RCT) undertaken in the
context of cardiometabolic disorders (obesity, T2D, CVD) to
investigate the following: (1) the effect of genetic risk testing
and communication on perceived and actual motivation to
engage in risk-reduction lifestyle modiﬁcation (diet and physi-
cal activity); and (2) the effect of genetic risk testing and com-
munication on actual lifestyle modiﬁcation and clinical
outcomes.
Methods
The protocol of this systematic review and meta-analysis was
registered with the University of York, Centre for Reviews and
Dissemination PROSPERO database (CRD42014009096)(17).
Eligibility
Types of participants. Given the limited knowledge of the
impact of genetic risk communication on multifactorial condi-
tions with reduced-penetrance susceptibility genetic variants
such as obesity, T2D and/or CVD, we were interested in
examining any individual, either healthy or at risk of these
disorders, in the context of disease prevention. No restrictions
were placed on age, sex or ethnicity.
Types of interventions and comparators. We deemed any
RCT assessing the provision of genetic risk prediction
information for the aforementioned disorders as eligible.
Studies could either involve a clinical genetic test, where
participants undertook a real genetic test and were provided
with their actual results or a vignette, which was deﬁned as a
hypothetical scenario providing a ﬁctitious but plausible
genetic risk.
The intervention (genetic risk information) could be com-
pared with either a control (no genetic risk information) or
alternative risk information (e.g. hormone or enzyme) or both.
Outcome measures. These included motivation for, or actual,
lifestyle behaviour change (diet, physical activity or health
screening) and any physiological or clinical outcome that would
result from this lifestyle behaviour change (e.g. change in body
weight, HbA1c or blood pressure).
As only RCT, representing the highest level of primary evi-
dence were included, studies of any other design, those relating
to new-born screening, family history analysis or investigating
the efﬁcacy of diet–gene interactions were excluded. Addictive
behaviours (e.g. smoking) and non-lifestyle-related behaviours
(e.g. medication adherence) were excluded.
Identiﬁcation of studies
All RCT published on this topic, between 2003 (following
completion of the Human Genome Project) and June 2015, were
identiﬁed without the limitation of language, length of intervention
and/or follow-up. Electronic searches using MEDLINE, PsycINFO,
EMBASE, CINAHL+ , Cochrane Central Register of Controlled
Trials combined search terms related to genetic risk, health
behaviour and either obesity, T2D and/or CVD (see the online
Supplementary material 1 for a sample search strategy). Inclusion
of both keywords and medical subject headings ensured a
comprehensive search. The grey literature was searched using the
key terms applied to MEDLINE, including ProQuest, Trove,
ETHOS and Science.gov. Reference lists from previous reviews
were also mined for eligible studies. Prominent authors identiﬁed
from subject knowledge and relevant reviews were searched
by name. Unpublished studies were identiﬁed via the WHO
International Clinical Trials Registry platform, and the authors of
completed but so far unpublished studies were contacted for
more information (via email and a reminder was sent if there was
no response after 2 weeks) (four contacted/one responded).
In addition, we contacted authors of published studies that had
incomplete data for our meta-analyses; thus, we attempted to
minimise publication bias (ﬁve contacted/four responded).
Study selection
Studies were screened by title and abstract by two independent
reviewers, against the eligibility criteria, and if selected by both
reviewers the full-text was reviewed. Any disagreements
regarding eligibility were resolved by discussion. All studies were
eligible for meta-analysis, but meta-analysis was only undertaken
if there were at least two studies assessing the same outcome.
Data collection
Data extraction for each study followed a standard procedure,
where two reviewers independently extracted data according to
a speciﬁc proforma (Table 1). Any discrepancies between the
reviewers were resolved by discussion, with the involvement of
two other reviewers when consensus could not be reached. If
investigated outcomes (as per protocol) were not reported
within their publication, authors were contacted to request for
further information.
Risk of bias assessment
Studies were assessed using the Cochrane Collaboration tool
for assessing risk of bias in RCT(18). A summary statement
indicating the sources of bias for each study was created
according to the key areas of bias advised (Table 2); two
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authors independently assessed bias at the study level. This
information was used to interpret ﬁndings as well as indications
for sensitivity analysis.
Measuring the effect of intervention and method of
analyses
Given that anticipated behaviours from hypothetical scenarios
do not necessarily result in actual behaviour change and this is a
known limitation of vignette studies(19), results from vignette
and clinical RCT are analysed and presented separately.
Therefore, we have distinguished between perceived v. actual
motivation for change to more accurately reﬂect the inter-
pretation of vignette and clinical studies, respectively. A pri-
marily narrative approach to analysis would be undertaken, as
pre-speciﬁed in the protocol, if high heterogeneity existed
between studies. A meta-analysis was conducted after homo-
genising comparable data (Stata Statistical Software, version 13;
StataCorp LP). The principal summary measure was standar-
dised mean difference (SMD), centred on 0, with values >0
favouring the intervention group (genetic risk communication)
and values <0 favouring the comparison group. To take into
account heterogeneity across studies, a random effects meta-
analysis was used by combining results for studies of varying
interventions(20). All the analyses were conducted using the
available case analysis(20). Where results were measured at
multiple time points, the furthest point in time was used in the
meta-analysis to represent effects on long-term behaviour
change. Heterogeneity was evaluated using χ2 tests and
I2 statistic. If high levels of heterogeneity existed, possible
sources of heterogeneity were identiﬁed (e.g. high risk of bias,
comparability of control group, method of risk communication)
followed by narrative rather than statistical sensitivity analysis.
Where possible, we have stratiﬁed analysis according to the
level of genetic risk, because genotype had been previously
identiﬁed as a potential effect modiﬁer(10). Formal statistical
publication bias was not undertaken because of insufﬁcient
number of studies per outcome of interest.
Results
Study selection
In total, 1967 unique citations were screened for inclusion, and
eleven publications, representing thirteen unique studies, form
this review (see Fig. 1 and Table 3).
Characteristics of included studies
Of the thirteen included trials, six were vignette studies
(hypothetical scenarios) and seven were clinical intervention
studies. This included one unpublished(21) and one semi-
published study(22) where authors agreed to contribute data.
The detailed characteristics of included trials are shown in
Table 3 and in the online Supplementary materials 2 and 3.
All participants were recruited from the general population,
where the majority of participants in vignette studies were
university students and in the clinical studies were middle aged;
four of the seven clinical studies recruited a ‘high-risk popula-
tion’ (e.g. overweight or met a criterion for having the metabolic
syndrome) but who did not have the condition of interest at
baseline(23–26). The average length of follow-up for clinical
studies was 6 months. On the basis of available case analysis,
the cumulative sample size for all studies was 8426, ranging
from 107(24) to 1607(22) (median 249).
Participants were either randomised to two groups, comparing
those provided with genetic test results and a control group
(either phenotypic risk feedback, standard healthy lifestyle
advice or no risk feedback), or three or more groups comparing
the aforementioned with feedback from an alternative test; two
of the vignette(27,28) and four of the clinical studies(21,24,25,29)
presented results stratiﬁed by the level of genetic-conferred
risk (online Supplementary materials 2 and 3). For example,
participants could possess 0, 1 or 2 risk alleles for a SNP
associated with the condition (e.g. fat mass and obesity
associated gene for obesity risk), or were categorised according
to a composite genetic risk score. Genetic risk was assigned
via a hypothetical scenario within vignette studies and by
genotyping within clinical studies. All outcomes of interest were
examined in studies investigating obesity and T2D, whereas four
studies assessed perceived motivation and actual behaviour
change in the context of CVD. A range of real and ﬁctitious
genetic variants was used.
Risk of bias
There were similar numbers of studies with low (n 5), high (n 4)
and unclear risk of bias (n 4) (Table 2). Vignette studies were
more prone to bias (three high risk, one low risk) than clinical
studies (one high risk, four low risk). Attrition bias was pre-
valent due to loss to follow-up and/or inadequate explanation
for excluding certain participants. In all, ﬁve clinical studies had
published protocols.
Table 1. Data extraction items
Items in the proforma Data items extracted
Background Source of funding, study design, aim
Method Location, number of participants, population characteristics, length of follow-up, source of genotyping/genetic risk counselling,
dietary assessment method, genetic assessment method, targeted disease, measurement of outcome, intervention (type of
genetic or alternative risk information) and comparator
Risk of bias Sequence generation for randomisation, allocation concealment, effective blinding, completeness of outcome data, free from
selective reporting, other biases
Results Mean, standard deviation, CI, P-value, adjustment for confounders
Conclusion Author conclusions and reviewers’ interpretation
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Trial outcomes
For each of the outcomes examined, results from the clini-
cal studies will be followed by results from the vignette
studies.
Motivation to change behaviour
Clinical studies. In clinical studies, ‘actual motivation’ was
assessed after participants undertook genetic testing and were
provided personalised genetic results. In the clinical studies,
Table 2. Summary of risk of bias judgements for studies included in this review
Vi
gn
et
te
 s
tu
di
es
Cl
in
ica
l s
tu
di
es
Frosch et al., 2005
(obesity)
Sanderson et al., 2010
(obesity)
Smerecnik et al., 2009
(hypertension and 
high cholesterol)
Dar-Nimrod et al., 2015
(obesity study 2
and 3)
Grant et al., 2013
(diabetes)
Marteau et al., 2004
(CVD)
Voils et al., 2015
(diabetes)
Meisel et al., 2015
(obesity)
Wang, unpublished
(obesity)
Food4Me
(Whitepaper, 2015
(obesity)
Hietaranta-Luoma
et al., 2015
(CVD)
Sufficient
sequence
generation?
Allocation
concealment?
Effective
blinding?
Incomplete
outcome
data
addressed?
Free from
selective
reporting?
Free from
other bias?
Overall
level of
bias?
Main risk of bias:
judgement
Limited detail in reporting
how allocation and
attrition treated
Limited detail in reporting
how allocation and
attrition treated
Limited detail in reporting
how allocation and
attrition treated
Well conducted study but
unclear exclusion of one
participant
Rigorously conducted
study
Well conducted study
except for use of self-
reported outcome measure
Rigorously conducted 
study but suitability of
comparison group unclear
Attrition leading to
inadequate power to
evaluate results
Well conducted trial
Rigorously conducted study
with high follow-up rate,
attention to psychological
methodology and validated
outcome measure
Well conducted study but
lack power and
consistency in method
NA
NA
NA
NANA
NA
NA
NA NA NA
NA NA
NA
NA
NA, not available; , low risk of bias; , unclear risk of bias; , high risk of bias.
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weight-loss motivations were mixed. In two of the studies
reviewed, participants who were provided genetic risk feedback
were reported to possess higher motivation to lose weight (Wang
et al., unpublished result) or stage of change for weight control
(OR 1·77; 95% CI 1·08, 2·89, P= 0·023) compared with con-
trols(21,29). In that study, motivation was accentuated in those
with a genotype for elevated risk (AA/AT v. control OR 2·38; 95%
CI 1·33, 4·26, P= 0·003)(29). This result was not evident in another
study where diabetes prevention was the focus(25). Similarly,
motivational intent for improving diet and exercise appeared
unaffected by genetic risk information across relevant studies(25).
These studies were not meta-analysed because of insufﬁcient
number of studies with comparable outcome measures.
Vignette studies. In vignette studies, participants’ ‘perceived
motivation’ was assessed after provision of a hypothetical genetic
test or supposed factual information about the genetic aetiology
of a disease. First, the effect of genetic risk information compared
with controls (not receiving genetic information) on motivation
for dietary modiﬁcation was examined in four studies(28,30).
Although both groups reported a high motivation to change (>7
out of 10 on a Likert scale), our random effects meta-analysis
showed that those with genetic risk information had a slight but
non-signiﬁcantly lower motivation to change compared with the
control (SMD −0·15; 95% CI −1·03, 0·73, P= 0·74) (Fig. 2 and
online Supplementary material 2)(28,30). High heterogeneity was
evident, I 2= 78%, P= 0·003, thereby reducing conﬁdence in the
pooled null ﬁnding. This may be due to a study with high risk of
bias and adopting a non-personalised approach in commu-
nicating risk(29). In addition, it may reﬂect age-related differences
where participants of studies favouring genetic risk were
younger (aged 20s) (Sanderson et al., and Smerecnick et al.,
study on hypertension A) compared with those favouring the
control (aged 40s) (Smerecnik et al., study on cholesterol and
hypertension B) who were older. Second, the difference in
‘perceived motivation’ for dietary modiﬁcation after provision of
risk from either a genetic test or an alternative test was also
examined. Meta-analysis of two studies with conﬂicting ﬁndings
showed a SMD of −0·04; 95% CI −0·37, 0·29, P= 0·82, with no
indication of heterogeneity (I 2= 0%) (Fig. 2)(27,28).
Actual behaviour change
Clinical studies. Among the six clinical studies with inter-
ventions ranging from 1 to 12 months, there were
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ilit
y
Id
en
tif
ica
tio
n Additional records identified 
through other sources (reference 
mining, grey literature, key author 
search)
(n 5)
Records screened
(n 1967)
Records excluded
(n 1892)
Full-text articles assessed 
for eligibility
(n 75)
Full-text articles excluded,
with reasons 
(n 64) 
Not genetic testing: 8 
Not outcome: 24 
Not target population: 6 
Not RCT: 15 
Protocols: 7 
Abstracts of protocols: 4 
Studies included in 
qualitative synthesis
(11 articles, 13 studies)
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n 8) 
Authors responded to 
request for additional data 
(4 published, 1 
unpublished)
Duplicates removed
(n 238)
Records identified through five 
electronic databases 
(n 2200)
Fig. 1. Flow chart of studies identified and included in the systematic review and meta-analysis. RCT, randomised controlled trials.
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inconsistencies regarding whether learning about genetic risk
alters dietary intake and/or physical activity (online Supple-
mentary material 3). Among them, three studies reported dif-
ferences in self-reported dietary intake between the genetic and
control groups(23,26,31) while two others did not(22,24).
The results from a study among 601 veterans at risk of T2D
reported a borderline statistically signiﬁcant difference in macro-
nutrient and total energy intakes at 3 months; however, this was
not reported to be sustained at 6 months (difference in log
energy −0·1; 95% CI −0·1, 0, P= 0·20)(23). In another study of
Study
Genetic testing v. control
Genetic testing v. alternative test
Sanderson et al., 2010
Sanderson et al., 2010
Smerecnik et al., 2009 (cholesterol)
Smerecnik et al., 2009 (hypertension-A)
Smerecnik et al., 2009 (hypertension-B)
Subtotal (I2= 78.0 %, P = 0.003)
Subtotal (I2= 0 %, P = 0.32)
Frosch et al., 2005
n
145
148
191
191
139
249
SMD    95 % CI
0.50   –0.07,   1.07
–0.94   –1.61, –0.27
0.70   –0.52,   1.92
0.80   –1.90,   0.30
–0.15   –1.03,   0.73
0.16   –0.35,   0.67
–0.18   –0.61,   0.25
–0.04   –0.37,   0.29
P = 0.74
P = 0.82
–2 –1 0 1 2
Favours control/alternative group Favours genetic group
Fig. 2. Summary of pooled standardised mean difference (SMD) in perceived motivation to change dietary behaviour via a random effects meta-analysis of vignette
studies (standardised Likert scale: 1–10). I 2, between-trial heterogeneity.
Table 3. Summary of studies reporting on genetic risk communication and lifestyle behaviour change
Outcomes Clinical studies* Vignette studies*
No. of
participants†
Average age
(years) Ethnicities reported
Perceived motivation to change behaviour
Obesity 0 Sanderson(28), Frosch(27) 440 24·9 White, Asian, African
American, others
T2D 0 0 0 –
CVD 0 Smerecnik(30) × 3 432 33·2
Total number 0 5 872
Actual motivation to change behaviour
Obesity Wang(21), Meisel(29) NA 975 35·5 African American, White,
others
T2D Grant(25) NA 108 58·7
CVD 0 NA 0 –
Total number 3 NA 1083
Risk reducing behaviour (dietary, physical activity or other)
Obesity Celis-Morales(22), Meisel(29) Dar-Nimrod(32) 2048 27·2 African American, White,
Asian, others
T2D Voils(23), Grant(25) 0 709 56·4
CVD Marteau(26),
Hietaranta-Luoma(24)
0 423 51·0
Total number 6 1 3180 –
Clinical outcome (BMI, weight loss, HbA1c)
Obesity Wang(21), Meisel(29), Celis-Morales(22) 0 2582 36·9 African American, White,
others
T2D Voils(23), Grant(25) 0 709 56·4
CVD 0 0 0 –
Total number 5 0 3291
Genetic loci examined (either
genotyped or used as within a
hypothetical scenario)
FTO, TCF7L2, PPARγ, KCNJ1, ApoE, LDAR, ApoB, GATA-2, FTO, KLF15 and a few fictitious genes
Total overall 14 6 8426 42·2
T2D, type 2 diabetes mellitus; NA, not applicable; FTO, fat mass and obesity associated gene; TCF7L2, transcription factor 7-like 2; KCNJ11, potassium channel, inwardly rectifying
subfamily J, member 11; LDAR, LDL receptor; GATA-2, GATA binding protein 2; KLF15, Kruppel-like factor 15.
* The last name of each study’s first author is listed.
† Number of participants based on available case analysis.
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316 probands (the ﬁrst family member affected by a genetic
disorder) who were diagnosed with familial hypercholester-
olaemia (with considerably high genetic penetrance for CVD),
the authors did not observe any difference in the proportion of
participants that chose to follow a low-fat diet 6 months after
genetic counselling(26). On the other hand, results from a four-
arm, web-based RCT (n 1269 healthy Europeans) reported that
overall dietary quality (Healthy Eating Index: genetic group was
1·4 units higher than the control, P< 0·01) and salt and fat
intakes signiﬁcantly improved in those who were provided
genetic risk information compared with controls(31). However,
the authors reported negligible differences between all perso-
nalised nutrition groups at the end of the study (levels 1–3;
online Supplementary material 3). Another Finnish study
(n 107) concurred with such inconsistencies. In a subgroup
analysis by genotype, they revealed that those possessing a
high-risk genotype (E4+) reported consuming greater quantities
of dietary fat compared with those with low-risk genotype
(E4−) and similarly compared with the control group
(P< 0·05)(24). Interestingly, no signiﬁcant difference was found
for quality of fat intake, vegetables and fruits, or alcohol
intake(24). Therefore, regardless of the limited number of studies
reviewed, there is an inconsistent impact of genetic risk on
dietary behaviour. Any beneﬁt of which appears short term and
only if compared with interventions lacking personalisation.
The heterogeneity in dietary intake measurement did not
enable meta-analysis for this outcome.
Of the ﬁve clinical studies(24–26,29) measuring changes in
physical activity after genetic risk communication, only one
reported their ﬁndings, indicating no substantial effect on
physical activity(24). Only one study precluded meta-analysis.
Vignette studies. A vignette study subjected 162 Canadian
undergraduate students to a psychological ‘cookie eating’
experiment(32). Participants were randomised into three groups
who received a newspaper article where obesity was described
on the basis of either (i) its genetic or (ii) its psychosocial
aetiology or (iii) a control where body weight was not
mentioned. Despite the hypothetical nature of this experiment,
the group that was inﬂuenced to consider obesity as genetically
driven consumed signiﬁcantly more cookies (mean 52·0
(SD 41·8) g) than the psychosocial group (mean 33·1 (SD 22·9) g,
P= 0·02) who were only marginally different to the control
group (mean 37·0 (SD 29·8) g, P= 0·08), after adjustment for sex,
age and self-reported BMI(32).
Clinical outcome
Clinical studies. Weight loss was examined in ﬁve clinical
studies, three of which investigated obesity prevention(21,29).
Preliminary results from the European study ‘Food4Me’
reported that there was no statistically signiﬁcant difference in the
6-month weight change between intervention and control groups,
including in those who were overweight and/or obese at
baseline(31). Our meta-analysis of three studies comparing those
provided genetic risk (either high or average risk) with control
groups demonstrated no difference (Fig. 3)(23,25,29). There was a
standard mean weight loss of 0·29kg in favour of the control
group, although with large uncertainty for those with high genetic
risk compared with control, 95% CI −0·74, 1·31, P=0·58, and
minimal heterogeneity (I 2=34%), and similar results were
observed for those at average genetic risk compared with control.
Other clinical indicators including insulin resistance(23) and
attendance at a diabetes prevention programme(25) did not differ
between those provided genetic risk information and controls.
Discussion
This review investigated the effect of communicating genetic
risk on lifestyle modiﬁcation for cardiometabolic disorders and
found no evidence that this information improved participants’
Study n
High genetic risk v. control
Average genetic risk v. control
Follow-up
(mths)
Grant et al., 2013
Grant et al., 2013
Meisel et al., 2015
Meisel et al., 2015
Voils et al., 2015
Voils et al., 2015
Subtotal (I 2= 34.4 %, P = 0.22)
Subtotal (I 2= 4.7 %, P = 0.35)
108
108
279
279
601
601
3
3
8
8
6
6
weight change  (kg) 95 % CI
–0.75   –2.55, 1.05
0.96   –0.49, 2.41
0.30   –0.66, 1.26
0.29   –0.47, 1.05
–0.10   –1.24, 1.04
1.26   –0.11, 2.63
–0.55   –2.55, 1.45
0.29   –0.74, 1.31
P = 0.58
P = 0.45
–3 –2 –1 0 1 2 3
Greater weight loss in genetic group Greater weight loss in control group
Difference in standard mean
Fig. 3. Summary of pooled standard mean difference in weight change between genetic v. control groups via a random effects meta-analysis of clinical studies (weight
change in kg). I 2, between-trial heterogeneity; mths, months.
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dietary or exercise behaviour. It included recent, available
clinical studies that build upon several related reviews, all of
which concluded that there was limited support for such
behavioural beneﬁts(10,13,33). Our ﬁndings are consistent with
the updated Cochrane Systematic Review for dietary (SMD 0·12;
95% CI −0·00, 0·24, P= 0·05) and physical activity behaviours
(SMD −0·03; 95% CI −0·14, 0·07, P= 0·54) (published whilst our
review was under consideration)(34). Our review complements
their results with two additional clinical RCT (Wang et al.,
unpublished results; Food4Me: n 1607)(21,22), on top of ﬁve
vignette studies. Moreover, given that all studies measured self-
reported behaviours, which are subject to recall bias, our
review extends beyond examining only behaviours to clinical
outcomes (i.e. weight loss) that may indirectly reﬂect changes in
lifestyle and non-lifestyle behaviours.
Motivation for behaviour change
Findings for actual motivations regarding weight change/con-
trol were mixed, with two clinical studies showing that this was
favourably inﬂuenced by genetic risk (Wang et al., unpublished
results)(29). The reason for this inconsistency may be explained
by two potential mediators and/or moderators relating to par-
ticipant characteristics: their initial level of motivation and their
genetic literacy. First, qualitative evidence suggests that baseline
motivational status may mediate motivational change, where
individuals with low baseline motivation have comparatively
less incentive to change lifestyle behaviour than those with
higher baseline motivation(35,36). A particular study demon-
strated a signiﬁcant beneﬁt of genetic risk communication on
weight-loss motivations only among those with underweight/
normal BMI (Wang et al., unpublished results). This suggests
that these participants may possess pre-existing motivations for
a healthy lifestyle, which may indicate the possible transferable
effect of motivation rather than an additive effect of genetic risk
communication. Second, there is strong evidence that genetic
literacy determines understanding of genetic risk and sub-
sequent motivation to pursue healthy behaviours(37,38). Vassy
et al.(38) noted that motivational response to low genetic risk
results were dependent upon the participant’s genetic literacy,
whereby those with low genetic literacy showed higher moti-
vation for lifestyle modiﬁcation. The two studies in our review
that identiﬁed a motivational beneﬁt from genetic risk com-
munication were provided as an online risk feedback(21,29),
whereas the study that did not replicate this ﬁnding employed a
qualiﬁed genetic counsellor to communicate risk(25). As the
probabilistic nature of genetic information is usually poorly
understood, with only 38% of US college-educated adults
accurately interpreting their risk, and much lower when deliv-
ered online than in person(39), this raises intriguing questions.
DTC genetic services, which mostly use web-based delivery,
have been criticised for their high literacy demands(40) and are
discouraged by several government organisations for providing
genetic information without health professional support(41).
Questions remain as to how much of this difference can be
attributed to the mode of delivery of risk information and
whether online services alone can accommodate and support
varying levels of genetic and health literacy.
Actual behaviour change
There were mixed ﬁndings for dietary behaviour from the
six clinical studies. Heterogeneity in type of dietary behaviour
(e.g. percentage of energy intake, healthy eating index)
precluded conducting a meaningful meta-analysis: three studies
reported a beneﬁt of genetic risk on adopting healthier
eating behaviour. One study identiﬁed temporary borderline
signiﬁcant effects(23). The second study suggested that the
process of personalisation (i.e. tailoring advice) rather than the
tool used to convey personalisation appears more important(31).
A third study highlighted modulation by level of genetic risk(24).
Indeed, within the studies reviewed, those that compared
different forms of personalised risk information (i.e. genetic
risk/counselling with an alternative risk/counselling)(23,25) did
not observe signiﬁcant differences in dietary behaviour, unlike
the studies that compared genetic risk/counselling with general
health advice(24,29). As personalising therapy is the basis of
client-centred approaches, which have been found to better
motivate change in various health behaviours and enhance
outcomes at least in the short term(42), this suggests that
any form of personalisation may be beneﬁcial in supporting
behaviour change.
Several non-RCT studies also fail to identify any effect of
genetic risk information on adopting healthy lifestyle beha-
viours, including a before-and-after study of 1325 employees
from a DTC company who were provided genetic risk infor-
mation but had no observed improvements in fat intake
(P= 0·34), exercise (P= 0·39) or disease-screening behaviour
(P= 0·43) at 12 months of follow-up(12,43). This ﬁnding concurs
with evidence from other multifactorial conditions such as
colorectal cancer(44). This lack of behaviour change has led
some to hypothesise that genetic risk itself may not be enough
and that the provision of lifestyle advice based on genetics for
how to mitigate this risk incurred by genetics would encourage
adoption of the desired behaviours. For example, Zeevi
et al.(45), recently suggested that further personalisation of
dietary advice using an algorithm derived from various personal
factors such as sleep–wake cycle, physical activity and gut
microbiota in addition to dietary habits can be used successfully
to moderate glycaemic response in adults when delivered by a
trained dietitian. This presents a new model for tailoring dietary
advice that may be more robust than genetic risk alone. How-
ever, the utility of personalised nutrition, particularly using
genetic data on behaviour change, is also unclear, with two
small clinical trials funded by nutrigenetic companies, reporting
improvements in self-reported dietary intake and BMI(3,46).
However, this was not replicated within a larger multinational
personalised nutrition RCT (Food4Me), which adopted country-
speciﬁc validated dietary assessment tools(31). Hence, given that
perceived risk (including that from genetic risk) does not
strongly inﬂuence behaviour change(47) and the limited ‘infor-
mation value’ derived from the low predictive power of known
genetic variants(36,48,49), it may be unreasonable to expect
genetic risk to have the profound impacts on behaviour that has
been claimed.
Finally, a clinical study reported that elevated genetic risk
resulted in higher consumption of dietary fat(24) and another
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that informed participants of the genetic aetiology of disease led
to increased unhealthy food consumption(32). This may be
explained by maladaptive coping in accordance with the
‘common sense model of illness cognition’, in which indivi-
duals’ belief about disease threats guides their prevention
behaviour – that is, people can cope with disease threats
broadly in two ways, either they reduce the threat by adapting
to healthy behaviours or they form maladaptive mechanisms
including fatalistic responses dependent on the perceived
controllability of the threat(50). However, recent meta-analyses
and qualitative studies together indicate a limited fatalistic
response after genetic risk feedback, measured by perceived
control and self-reported fatalism(51–53). Hence, this ﬁnding
raises concern and warrants further testing and monitoring.
Strengths and limitations of the review
This review strived to be comprehensive and included both
published and unpublished literature, with efforts made to
contact authors where necessary. Although the scope for pub-
lication bias may have been reduced considerably by direct
correspondence with researchers and inclusion of previously
unreported data, we recognise that residual publication bias
deserves consideration and caution when interpreting results.
However, there was an insufﬁcient number of studies included
to formally test for publication bias. None of the clinical studies
examined potential mediators of behaviour change relevant to
genetic testing, including genetic and health literacy and
numeracy, and only two studies assessed baseline motiva-
tions(21,29). Understanding how participants with differing
characteristics respond to genetic information could assist in
tailoring future delivery. The meta-analyses should be inter-
preted bearing in mind two limitations – one being that the
heterogeneity in the data (i.e. measured outcome, condition
and methods) restricted quantitative synthesis of all outcomes
examined in the review, and two it was composed primarily of
small studies based on the currently available literature. There
was a lack of objectively measured behaviours, and the
resulting measurement error of self-reported methods pre-
vented ﬁrm conclusions to be drawn(54). Hence, we look
forward to the results from several ongoing studies that
will provide the much-needed insight using objective
methods(22,55,56). Finally, none of the studies were from
countries outside of the USA, Canada and Europe, which
interestingly coincides with the availability of commercial
personalised nutrition companies(57). At present, an on-going
study in Hong Kong will provide some much-needed
perspectives from Asia(58).
Further results from a meta-analysis on the effect of genetic
risk on perceived control, effectiveness of intervention and risk
can be found in the online Supplementary material 4.
Conclusions, implications and recommendations for
practice and research
On the basis of the totality of the evidence currently available
for inclusion within this review, including both the
meta-analyses and narrative synthesis, we found no clear or
consistent evidence that genetic risk communication alone
either raises motivation or translates into actual behaviour
change to reduce the risk of cardiometabolic disorders in adults.
With genetics proposed to inﬂuence health in multiple ways(59),
including genetic personalised nutrition(1) accompanied by
public enthusiasm, the incorporation of genetic risk into prac-
tice is likely to rise. Although we caution against unsupported
online provision of genetic risk because of the lack of
demonstrated clinical utility and possible negative implications,
in the interim with absence of such evidence, dietitians/nutri-
tionists may consider exploiting public enthusiasm in genetic
risk as another opportunity to educate across a range of pre-
ventative lifestyle behaviours. This will require upskilling of the
workforce in the area of genetics and genomics as we have
previously demonstrated(60,61).
Clearly, research is needed to untangle the effects that
can be attributed to methods of personalisation from genetic
risk communication for the impact on actual behaviour
change. Speciﬁcally, larger-scale, high-quality clinical RCT with
objective outcome measures are warranted. Participants should
also be more thoroughly characterised to capture risk
comprehension and initial level of motivation to enable health
professionals to better tailor their risk feedback to these.
Evaluation of clinical utility, alongside analytical and clinical
validity, in addition to the ethical, legal and social implications
of genetic testing, according to the Centre for Disease Control’s
ACCE framework(62), are current areas of enquiry. Finally, to
ensure public welfare in engaging with genetic susceptibility
information, policy makers need to enforce stricter regulation of
DTC services, which could start by setting clear European
frameworks.
Supplementary material
For supplementary material/s referred to in this article, please
visit http://dx.doi.org/doi:10.1017/S0007114516002488
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